In vitro interference of tigecycline at subinhibitory concentrations on biofilm development by Enterococcus faecalis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1155-1158

  Maestre, Juan Ramón ^a   Aguilar, Lorenzo ^b   Mateo, María ^a   Giménez, María José ^b   Méndez, María Luisa ^a   Alou, Luis ^b   Granizo, Juan José ^c   Prieto, José ^b  

^a HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c Grana Datos SL   (Spain)

Author keywords

Enterococcus; Glycylcyclines; Slime

Indexed keywords

CRYSTAL VIOLET; TIGECYCLINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTICAL DENSITY; SPECTROPHOTOMETRY;

ANTI-BACTERIAL AGENTS; BIOFILMS; CULTURE MEDIA; ENTEROCOCCUS FAECALIS; GENTIAN VIOLET; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SPECTROPHOTOMETRY; STAINING AND LABELING;

EID: 84859622510     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks014     Document Type: Article

References (10)

1. Sandoe JA, Wysome J, West AP et al. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother 2006; 57: 767-70.
2. Wiederhold NP, Coyle EA, Raad II et al. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemia. J Antimicrob Chemother 2005; 55: 792-5.
3. Dowzicky MJ, Chmelarǒvá E. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Int J Antimicrob Agents 2011; 37: 562-6.
4. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Growth Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
5. Mateo M, Maestre JR, Aguilar L et al. Strong slime production is a marker of clinical significance in Staphylococcus epidermidis isolated from intravascular catheters. Eur J Clin Microbiol Infect Dis 2008; 27: 311-4.
6. Sandoe JA, Witherden IR, Cove JH et al. Correlation between enterococcal biofilm formation in vitro and medical-device-related infection potential in vivo. J Med Microbiol 2003; 52: 547-50.
7. Seno Y, Kariyama R, Mitsuhata R et al. Clinical implications of biofilm formation by Enterococcus faecalis in the urinary tract. Acta Med Okayama 2005; 59: 79-87.
8. Sevillano D, Aguilar L, Alou L et al. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Int J Antimicrob Agents 2010; 36: 137-44.
9. Rubino CM, Ma L, Bhavnani SM et al. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob Agents Chemother 2007; 51: 4085-9.
10. Minardi D, Cirioni O, Ghiselli R et al. Efficacy of tigecycline and rifampin alone and in combination against Enterococcus faecalis biofilm infection in a rat model of ureteral stent. J Surg Res 2011; doi:10.1016/j.jss.2011.05.002.